Mycomycen (Ciclopirox Olamine)

Ciclopirox olamine interferes with fungal enzyme activity and disrupts membrane transport processes, which impairs the synthesis of essential cellular components. This dual action halts fungal growth and leads to the death of Candida species present in the vaginal mucosa.

The dosage regimen for Mycomycen is determined by the prescribing healthcare professional based on the severity of infection and patient‑specific factors. The prescriber will specify the amount, frequency, and duration of vaginal application in the treatment plan.

Safety data for ciclopirox olamine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before initiating therapy.

To request Mycomycen, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mycomycen’s active ingredient, ciclopirox olamine, offers a broad spectrum of activity against Candida species and works by a distinct mechanism compared with azole antifungals such as fluconazole. It is applied locally, which can reduce systemic exposure, but selection of therapy depends on infection severity, resistance patterns, and patient tolerance.

Mycomycen should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity.

Mycomycen is applied intravaginally as directed by the prescriber. Typically, the patient inserts the specified amount of the formulation into the vagina using an applicator or fingertip, ensuring even distribution across the mucosal surface, and follows the prescribed frequency and treatment duration.

Although rare, serious adverse reactions can include severe allergic responses such as anaphylaxis, extensive swelling of the vulvar or vaginal tissues, and intense burning or pain. Patients should seek immediate medical attention if they experience signs of a severe reaction.

Mycomycen should be avoided by individuals with a known hypersensitivity to ciclopirox olamine or any component of the formulation. It is also not recommended for use in patients with untreated severe vaginal infections or those who have contraindications identified by their healthcare provider.